PatientView study on biosimilars presented at European Commission workshop

shutterstock_269042549

On 6 October 2015 the European Commission´s  Directorate General for Internal Market, Industry, Entrepreneurship and SMEs (DG GROW), organized a workshop on Access to and Uptake of Biosimilar Medicinal Products.

The objective of the workshop were to gather all relevant interested parties in order to facilitate a multi-stakeholder exchange of information, experiences and reflection on the state of play and explanations for differences in market uptake amongst the EU Member. In particular, to give a floor for patients, doctors and payers to express their views on biosimilar related developments at European but also at national level and to stimulate an open discussion and explore needs for action and in particular with regard to further political activities and initiatives at European level.

EFCCA (European Federation of Crohn’s and Colitis) chairman, Marco Greco, opened the panel session with a presentation stressing the importance of good-quality information that meets patients’ needs. He also called for shared decision-making and patient-professional communication to increase trust and enable patients to make informed decisions.  See http://efcca.org/index.php/multimedia/breaking-news/134-efcca-at-european-commission-workshop-on-biosimilars

PatientView was pleased to be able to present its latest study on the views of 110 patient groups on biosimiliars. Just click on link below to view the presentation:

October 6 EC event FINAL 01.10.15

A complete set of presentations at the Commission workshop was also released today see

http://ec.europa.eu/DocsRoom/documents/14553